BLFS Share Price Performance
US$25.41
-1.86 (-6.82%)
18.5% undervalued intrinsic discount
US$31.16
Fair Value
Price US$25.41
AnalystConsensusTarget US$31.16
Fair ValueUS$31.30
Share Pricen/a
BioLife Solutions, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
BLFS Community Narratives
AN
Fair Value US$31.3 18.8% undervalued intrinsic discount
Cell And Gene Therapies Will Unlock Biopreservation Potential
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Cell And Gene Therapies Will Unlock Biopreservation Potential
Key Takeaways Cross-selling of integrated products and new technology adoption are increasing customer retention and boosting both revenue per dose and overall margins. Strategic acquisitions and a growing regenerative medicine market position BioLife for sustained revenue growth and strengthened market leadership.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$31.3
18.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
19.95% p.a.
Profit Margin
20.59%
Future PE
60.33x
Price in 2028
US$37.97
Trending Discussion
Recently Updated Narratives
AN
Cell And Gene Therapies Will Unlock Biopreservation Potential
Fair Value: US$31.3 18.8% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioLife Solutions, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.37
- 64.28%
- -17.80%
- 2.1%
About BLFS
- Founded
- 1987
- Employees
- 159
- CEO
- WebsiteView website
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
